@article{3111954,
    title = "A systematic review of oral fungal infections in patients receiving cancer therapy",
    author = "Lalla, R.V. and Latortue, M.C. and Hong, C.H. and Ariyawardana, A. and D'Amato-Palumbo, S. and Fischer, D.J. and Martof, A. and Nicolatou-Galitis, O. and Patton, L.L. and Elting, L.S. and Spijkervet, F.K.L. and Brennan, M.T.",
    journal = "Supportive Care in Cancer",
    year = "2010",
    volume = "18",
    number = "8",
    pages = "985-992",
    issn = "0941-4355, 1433-7339",
    doi = "10.1007/s00520-010-0892-z",
    keywords = "amifostine;  amphotericin B;  clotrimazole;  fluconazole;  itraconazole;  micafungin;  nystatin;  placebo, cancer chemotherapy;  cancer radiotherapy;  cancer therapy;  cost effectiveness analysis;  drug cost;  drug efficacy;  fungal colonization;  head and neck cancer;  health care cost;  hematopoietic stem cell transplantation;  human;  infection prevention;  infection risk;  intervention study;  mouth hygiene;  mouth infection;  mouth inflammation;  mycosis;  observational study;  outcome assessment;  patient care;  priority journal;  quality control;  quality of life;  review;  risk assessment;  systematic review;  thrush;  treatment planning, Antifungal Agents;  Candidiasis, Oral;  Health Care Costs;  Humans;  Neoplasms;  Oropharynx;  Pharyngeal Diseases;  Quality of Life;  Risk Factors",
    abstract = "Purpose: The aims of this systematic review were to determine, in patients receiving cancer therapy, the prevalence of clinical oral fungal infection and fungal colonization, to determine the impact on quality of life and cost of care, and to review current management strategies for oral fungal infections. Methods: Thirty-nine articles that met the inclusion/exclusion criteria were independently reviewed by two calibrated reviewers, each using a standard form. Information was extracted on a number of variables, including study design, study population, sample size, interventions, blinding, outcome measures, methods, results, and conclusions for each article. Areas of discrepancy between the two reviews were resolved by consensus. Studies were weighted as to the quality of the study design, and recommendations were based on the relative strength of each paper. Statistical analyses were performed to determine the weighted prevalence of clinical oral fungal infection and fungal colonization. Results: For all cancer treatments, the weighted prevalence of clinical oral fungal infection was found to be 7.5% pretreatment, 39.1% during treatment, and 32.6% after the end of cancer therapy. Head and neck radiotherapy and chemotherapy were each independently associated with a significantly increased risk for oral fungal infection. For all cancer treatments, the prevalence of oral colonization with fungal organisms was 48.2% before treatment, 72.2% during treatment, and 70.1% after treatment. The prophylactic use of fluconazole during cancer therapy resulted in a prevalence of clinical fungal infection of 1.9%. No information specific to oral fungal infections was found on quality of life or cost of care. Conclusions: There is an increased risk of clinically significant oral fungal infection during cancer therapy. Systemic antifungals are effective in the prevention of clinical oral fungal infection in patients receiving cancer therapy. Currently available topical antifungal agents are less efficacious, suggesting a need for better topical agents. © Springer-Verlag 2010."
}